LAC23 Antibody

What is LAG-3 and why is it significant in immunology research?

LAG-3 (Lymphocyte activation gene-3), also known as CD223, is a member of the immunoglobulin superfamily (IgSF) that functions as an immune checkpoint molecule. The mature LAG-3 protein is a 496 amino acid membrane protein with a 421 amino acid extracellular region containing four IgSF domains, a 21 amino acid transmembrane region, and a 54 amino acid cytoplasmic region . Its significance stems from its role as a negative regulator of T cell activation, binding to MHC class II with higher affinity than CD4. Studies using LAG-3-/- mice have demonstrated significant delay of T cell apoptosis following antigen stimulation and increased size of memory T cell pools following infection, highlighting its importance in immune regulation . As an immune checkpoint, LAG-3 has become a target for cancer immunotherapy development alongside other checkpoint molecules.

How does LAG-3 expression differ between cell types in the immune system?

LAG-3 is primarily an activation-induced molecule, with expression patterns distinctly different from its structural relative CD4. It is expressed on activated T cells and NK cells but notably absent on resting T cells . Research has demonstrated that LAG-3 is selectively expressed on activated CD4+CD25+ T regulatory cells and plays a significant role in their suppressive activity . In human tissues, LAG-3 expression has been detected in lymphocytes within the spleen, as confirmed by immunohistochemical staining . The differential expression pattern of LAG-3 makes it a valuable marker for identifying specific activated immune cell populations and studying immune regulation mechanisms.

What are the fundamental structural similarities and differences between LAG-3 and CD4?

Despite sharing less than 20% amino acid sequence homology, LAG-3 and CD4 display remarkable structural similarities . Both proteins bind to MHC class II molecules, though LAG-3 does so with significantly higher affinity than CD4. Structurally, both contain immunoglobulin-like domains in their extracellular regions, though LAG-3 contains four such domains compared to CD4's structure. Interestingly, the genes for both proteins are located on the distal part of the short arm of chromosome 12, suggesting a possible evolutionary relationship . The key functional difference is that while CD4 engagement with MHC class II enhances T cell activation, LAG-3 binding to MHC class II molecules appears to negatively regulate T cell responses, indicating opposing roles in immune regulation despite their structural similarities.

What are the optimal conditions for using LAG-3 antibodies in flow cytometry?

For optimal flow cytometry application of LAG-3 antibodies, researchers should consider several technical parameters:

For experiments with human samples, treating PBMCs with PHA (1 μg/mL for 5 days) has been shown to induce LAG-3 expression to detectable levels . When working with transfected cell lines like HEK293, appropriate controls including irrelevant transfectants should be used to establish accurate quadrant markers . For membrane-associated proteins like LAG-3, gentle permeabilization protocols should be employed if intracellular domains need to be detected.

How should researchers validate the specificity of LAG-3 antibodies in their experimental system?

Validating antibody specificity is critical for generating reliable research data. For LAG-3 antibodies, a multi-pronged validation approach is recommended:

• Positive and negative control samples: Include LAG-3-transfected cells (e.g., HEK293 cells transfected with human LAG-3) alongside non-transfected controls or irrelevant transfectants . The clear differential staining pattern confirms antibody specificity.

• Stimulation experiments: Compare resting T cells (which should be LAG-3 negative) with activated T cells (which should upregulate LAG-3) . This physiological induction serves as a biological validation of specificity.

• Knockout or knockdown controls: Where possible, include LAG-3 knockout samples or cells treated with LAG-3-targeting siRNA to demonstrate absence of staining when the target is removed.

• Peptide blocking: Pre-incubation of the antibody with purified LAG-3 protein should abolish specific staining in positive samples.

• Cross-reactivity testing: Especially important if working across species, testing against cells known to lack LAG-3 or express highly homologous proteins helps establish specificity boundaries.

Documentation of these validation steps is essential for publication and should be included in materials and methods sections.

What protocols are effective for detecting LAG-3 in tissue sections using immunohistochemistry?

For effective immunohistochemical (IHC) detection of LAG-3 in tissue sections, the following protocol has been validated for human spleen sections and can be adapted for other tissues:

• Sample preparation: Use immersion-fixed, paraffin-embedded tissue sections (optimal thickness 4-6 μm).

• Epitope retrieval: Perform heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (pH >8.0) prior to antibody incubation, as LAG-3 epitopes are often masked during fixation .

• Primary antibody: Apply LAG-3 antibody at 3 μg/mL concentration and incubate for 1 hour at room temperature .

• Detection system: For human samples, an anti-goat IgG HRP polymer detection system has shown excellent results when used with DAB (3,3'-diaminobenzidine) as the chromogen .

• Counterstaining: Use hematoxylin for nuclear visualization, which provides good contrast with the brown DAB signal.

• Controls: Include isotype controls and known positive and negative tissues to validate staining patterns.

In human spleen, specific LAG-3 staining localizes to lymphocytes , providing a useful positive control tissue. When adapting this protocol to other tissues, optimization of antibody concentration and incubation times may be necessary to achieve optimal signal-to-noise ratio.

How can computational modeling be integrated with experimental approaches to improve LAG-3 antibody specificity?

Integrating computational modeling with experimental approaches represents a cutting-edge strategy for developing highly specific LAG-3 antibodies. Recent advances demonstrate how this combined approach can yield superior results:

Computational methods can identify distinct binding modes associated with specific ligands, enabling the prediction and generation of antibody variants beyond those observed in conventional experimental selection . This approach involves:

• Initial experimental data collection: Using phage display to select antibody libraries against various combinations of LAG-3 and structurally similar ligands.

• Model training: Developing biophysics-informed models trained on experimentally selected antibodies that associate distinct binding modes with potential ligands.

• Computational prediction and design: Using the trained model to both predict outcomes for new ligand combinations and generate antibody variants with customized specificity profiles not present in the initial library .

• Experimental validation: Testing computationally designed variants to verify their specificity profiles.

This integrated approach has successfully generated both highly specific antibodies (that interact with a single ligand while excluding others) and cross-specific antibodies (that interact with multiple distinct ligands) . The key advantage is the ability to disentangle multiple binding modes associated with chemically similar targets, which is particularly valuable when working with complex immune checkpoint molecules like LAG-3 that share structural similarities with other proteins.

What are the critical considerations when designing experiments to study LAG-3's role in T regulatory cell function?

Designing experiments to study LAG-3's role in T regulatory (Treg) cell function requires careful consideration of several critical factors:

When studying LAG-3's specific contribution to Treg function, it's essential to include appropriate controls that distinguish its effects from other suppressive mechanisms. Studies have demonstrated that LAG-3 plays a significant role in the suppressive activity of CD4+CD25+ Treg cells , but understanding its precise mechanism requires blocking experiments with anti-LAG-3 antibodies while preserving other Treg functional elements. Additionally, comparing LAG-3+/+ with LAG-3-/- Tregs in adoptive transfer experiments can provide insights into its role in vivo, as LAG-3 deficiency has been shown to affect T cell apoptosis timing and memory pool size .

How can researchers effectively use LAG-3 antibodies to investigate the interplay between LAG-3 and MHC class II signaling?

Investigating the complex interplay between LAG-3 and MHC class II signaling requires sophisticated experimental approaches that address both sides of this interaction:

• Bidirectional signaling analysis: LAG-3/MHC-II interaction generates signals in both the LAG-3-expressing T cell and the MHC-II-expressing antigen-presenting cell (APC). Design experiments that capture both:

  • T cell side: Measure T cell activation markers, proliferation, and cytokine production with and without LAG-3 blockade

  • APC side: Assess dendritic cell maturation markers and monocyte cytokine secretion following LAG-3 engagement

• Domain-specific antibodies: Utilize antibodies targeting different LAG-3 domains to dissect which regions are critical for MHC-II binding versus signaling. The extracellular region contains four IgSF domains, and understanding domain-specific functions can reveal mechanistic insights .

• Competing ligand studies: LAG-3 binds MHC-II with higher affinity than CD4 . Experiments comparing the effects of LAG-3 and CD4 blockade separately and in combination can reveal whether these molecules compete for MHC-II binding or operate through distinct mechanisms.

• Mutational analysis: Generate LAG-3 variants with mutations in key binding residues to establish structure-function relationships in MHC-II interaction.

Research has shown that while LAG-3 negatively regulates T cell activation through LAG-3 signaling, it simultaneously stimulates antigen-presenting cells through MHC class II signal transduction . This dual role makes LAG-3 a fascinating target for immunotherapy, as blocking this interaction could potentially enhance T cell responses while modulating APC function.

What strategies can address poor LAG-3 detection in flow cytometry experiments?

Poor LAG-3 detection in flow cytometry is a common challenge that can be addressed through several optimization strategies:

• Activation status: LAG-3 is primarily expressed on activated T cells and NK cells, not resting T cells . Ensure adequate cell activation using PHA (1 μg/mL for 5 days for human PBMCs) or other relevant stimuli for your cell population .

• Epitope masking: LAG-3 may interact with other surface proteins or undergo conformational changes that mask antibody binding sites. Try multiple antibody clones targeting different epitopes.

• Antibody titration: Optimal concentration is crucial; too high may increase background, too low may miss positive populations. Perform a titration series (typically from 0.1-10 μg/mL) to determine optimal signal-to-noise ratio.

• Buffer optimization: Include protein (0.5-1% BSA) in staining buffer to reduce non-specific binding. Some epitopes may be sensitive to sodium azide; try fresh buffers without preservatives.

• Fixation considerations: If fixing cells, use mild fixatives (0.5-1% paraformaldehyde) as harsh fixation can destroy LAG-3 epitopes. For certain applications, staining prior to fixation may yield better results.

• Compensation settings: When using multiple fluorophores, ensure proper compensation to prevent false positives/negatives. APC-conjugated LAG-3 antibodies may require careful compensation with PE channels .

• Instrument settings: Optimize PMT voltages specifically for the fluorophore used with your LAG-3 antibody to ensure detection within the optimal range of the instrument.

If detection remains challenging after these optimizations, consider enriching for LAG-3-positive populations prior to analysis or switching to more sensitive detection methods like spectral cytometry.

How can researchers resolve discrepancies between LAG-3 detection methods in their experimental systems?

Resolving discrepancies between different LAG-3 detection methods requires systematic troubleshooting and understanding the limitations of each approach:

• Epitope accessibility variations: Different detection methods expose cells to different conditions that affect epitope accessibility. Flow cytometry examines surface expression on intact cells, while Western blotting detects denatured protein, and IHC looks at fixed tissue contexts. These fundamental differences can lead to apparently conflicting results.

  Solution: Use multiple antibody clones recognizing distinct epitopes across different regions of LAG-3. Compare results between methods using the same clone when possible.

• Expression threshold differences: Each method has different sensitivity thresholds. Flow cytometry typically detects approximately 500-1000 molecules per cell, while amplification steps in IHC or ELISA may detect lower expression levels.

  Solution: Quantify expression using calibration beads for flow cytometry and standard curves for ELISA to establish absolute quantities for comparison.

• Contextual expression variations: LAG-3 expression is highly context-dependent, varying with activation state and microenvironment. In vitro vs. in vivo expression patterns often differ significantly.

  Solution: Directly compare samples prepared identically and processed in parallel through different detection methods. Use positive controls with known high LAG-3 expression, such as activated T cells or LAG-3-transfected cell lines .

• Post-translational modification detection: Different antibodies may preferentially recognize certain glycosylation or phosphorylation states of LAG-3.

  Solution: Use enzymatic treatments (e.g., glycosidases) to remove post-translational modifications before detection, or specifically choose antibodies validated for detecting the modified forms of interest.

When publishing results showing method discrepancies, clearly document the specific antibody clones, detection methods, and experimental conditions to help the research community interpret seeming contradictions in LAG-3 expression data.

What are the key considerations for developing LAG-3 blocking antibodies for immunotherapy research?

Developing effective LAG-3 blocking antibodies for immunotherapy research requires attention to several critical parameters:

• Epitope selection: Target epitopes that directly interfere with LAG-3's interaction with MHC class II or other ligands. Structural studies have identified the LAG-3 binding domains that interact with MHC-II, making these regions priority targets for blocking antibody development .

• Affinity optimization: Higher affinity generally correlates with better blocking capacity, but extremely high affinity may reduce tissue penetration in vivo. Aim for sub-nanomolar affinities while maintaining favorable pharmacokinetics.

• Isotype selection: For in vivo studies, the antibody isotype significantly impacts function:

  • IgG1 provides effector functions (ADCC/CDC) that may deplete LAG-3+ cells

  • IgG4 minimizes effector functions, focusing on blocking activity

  • F(ab) fragments eliminate Fc-mediated effects entirely

• Cross-reactivity assessment: If intended for translational research, evaluate cross-reactivity with LAG-3 from relevant model species. Despite structural similarities, antibodies against human LAG-3 often fail to recognize murine LAG-3 due to sequence differences.

• Functional validation hierarchy:

  Validation Level	Assay Type	Key Measurement
  Basic	Binding assays	Affinity (KD) to recombinant LAG-3
  Intermediate	Cell-based blocking	Inhibition of LAG-3/MHC-II interaction
  Advanced	Functional rescue	Restoration of T cell proliferation/cytokine production
  Translational	In vivo models	Tumor regression, immune infiltration

• Combination assessment: LAG-3 blockade often shows synergy with other checkpoint inhibitors, particularly PD-1 pathway blockers. Evaluating combinations in functional assays provides valuable insights for immunotherapy applications.

Recent computational approaches to antibody design represent a promising direction for developing highly specific LAG-3 blocking antibodies with customized specificity profiles . These methods allow for the design of antibodies that can selectively block LAG-3 without cross-reactivity to structurally similar proteins, potentially reducing off-target effects in immunotherapy applications.

How does the bispecific antibody approach enhance LAG-3 targeting in cancer immunotherapy research?

Bispecific antibody approaches represent a cutting-edge strategy for enhancing LAG-3 targeting in cancer immunotherapy research, offering several advantages over conventional monospecific antibodies:

• Simultaneous checkpoint blockade: LAG-3/PD-1 bispecific antibodies can block two inhibitory pathways simultaneously, addressing the challenge of compensatory upregulation that often occurs when only one pathway is blocked. This dual blockade has shown superior T cell reinvigoration compared to individual antibodies or combinations.

• Enhanced tumor targeting: Bispecifics combining LAG-3 with tumor-associated antigens (TAAs) can increase local concentration of checkpoint blockade within the tumor microenvironment, potentially reducing systemic immune-related adverse events while maintaining efficacy.

• Improved pharmacokinetics and biodistribution: Single-molecule bispecifics demonstrate different tissue penetration properties compared to co-administered monospecific antibodies, potentially enhancing delivery to tumor sites.

• Novel mechanisms of action: LAG-3/CD3 bispecifics can simultaneously recruit T cells to tumor sites while blocking inhibitory signals, creating potent anti-tumor responses that neither modality could achieve alone.

• Formatting flexibility: Various bispecific formats (e.g., IgG-scFv fusions, diabodies, tandem scFvs) provide options for optimizing molecular weight, valency, and geometry based on the specific application.

Recent computational approaches to antibody design could be particularly valuable for bispecific development, as they enable the identification of different binding modes and the generation of antibodies with customized specificity profiles . This targeted design can help overcome challenges in bispecific development such as maintaining dual specificity without compromising affinity for either target.

What are the methodological challenges in studying LAG-3's interaction with its ligands beyond MHC class II?

Studying LAG-3's interactions with alternative ligands presents several methodological challenges that require specialized approaches:

• Low-affinity interaction detection: Many LAG-3 interactions with non-MHC-II ligands may be of lower affinity, making traditional binding assays insufficiently sensitive. Surface plasmon resonance with covalently coupled proteins, bio-layer interferometry with high ligand densities, or proximity-based assays (AlphaScreen, FRET) may be required for reliable detection.

• Context-dependent binding: LAG-3 interactions may be highly influenced by the cellular context, microenvironment, or activation state, necessitating more physiologically relevant assay systems than purified protein interactions.

• Competitive binding analysis: Distinguishing specific binding from non-specific interactions requires carefully designed competition assays with known ligands (MHC-II) and potential novel ligands.

• Post-translational modification considerations: LAG-3 undergoes extensive glycosylation which may influence binding to certain ligands. Comparing bacterially-expressed (non-glycosylated) versus mammalian-expressed (glycosylated) LAG-3 in binding studies is essential.

• Structural biology challenges: LAG-3's flexible structure makes crystallography difficult, and its size challenges NMR analysis. Cryo-EM approaches combined with hydrogen-deuterium exchange mass spectrometry may provide better structural insights into ligand binding.

• Validation in cellular systems: Binding detected in biochemical assays requires validation in cellular systems where both LAG-3 and its ligand are expressed in their native context. CRISPR-based knockout of candidate ligands in relevant cell types can provide definitive evidence of functional interactions.

Advances in computational approaches to protein-protein interactions could help overcome some of these challenges by predicting potential binding interfaces and allowing more targeted experimental designs . These models, trained on experimental data, can identify different binding modes associated with specific ligands, potentially revealing interactions that might be missed in traditional binding assays.

How can single-cell analysis techniques enhance our understanding of LAG-3 function in the tumor microenvironment?

Single-cell analysis techniques offer unprecedented insights into LAG-3 biology within the complex tumor microenvironment:

• Single-cell RNA sequencing (scRNA-seq) reveals LAG-3 expression heterogeneity across immune cell subpopulations and correlates its expression with other checkpoint molecules, exhaustion markers, and functional states. This can identify previously unrecognized LAG-3-expressing populations and potential compensatory mechanisms following checkpoint blockade.

• Cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) combines surface protein detection (including LAG-3) with transcriptome analysis, allowing researchers to correlate LAG-3 protein expression with transcriptional programs at single-cell resolution.

• Single-cell spatial transcriptomics maintains tissue context while providing gene expression data, enabling visualization of LAG-3+ cells relative to tumor cells, vasculature, and other immune populations. This reveals spatial relationships that may influence LAG-3 function.

• Imaging mass cytometry (IMC) or multiplexed ion beam imaging (MIBI) can simultaneously visualize dozens of proteins, allowing comprehensive phenotyping of LAG-3+ cells within their native tissue architecture. This technique can reveal co-expression patterns of multiple checkpoint molecules at single-cell resolution.

• Functional single-cell approaches like single-cell cytokine secretion assays can directly correlate LAG-3 expression with functional outputs, addressing the critical question of whether LAG-3 expression always indicates functional exhaustion.

These techniques are particularly valuable when applied to clinical samples before and after LAG-3-targeted therapy, potentially identifying biomarkers of response and resistance mechanisms. By integrating multiple single-cell modalities, researchers can develop a comprehensive understanding of LAG-3's role within the complex cellular ecosystem of the tumor microenvironment, informing more effective therapeutic strategies.